



**COVERAGE DETERMINATION REQUEST FORM**

**EOC ID:**

Non Formulary Exception (NFE) Request-8A Medicare

**Phone: 866-250-2005 Fax back to: 877-503-7231**

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b>	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

**\*Please note that Elixir will process the request as written, including drug name, with no substitution.**

Drug Name and Strength:  **REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the standard review timeframes (72 hours for initial requests or 7 days for appeals) may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.**

Directions / SIG:

**Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.**

<p>Q1. Is the drug being requested for initial therapy or continuing therapy?</p> <p><input type="checkbox"/> Initial therapy <input type="checkbox"/> Continuing therapy</p>
<p>Q2. For CONTINUING THERAPY, please provide the start date:</p>
<p>Q3. What is the patient's diagnosis for the requested medication?</p>
<p>Q4. Does the patient reside in a Long Term Care Facility or at home?</p> <p><input type="checkbox"/> Long Term Care Facility  <input type="checkbox"/> Home residence  <input type="checkbox"/> None of the above</p>
<p>Q5. What is the anticipated duration of therapy?</p> <p><input type="checkbox"/> Less than a month  <input type="checkbox"/> One to three months  <input type="checkbox"/> Three months to one year  <input type="checkbox"/> Lifetime</p>
<p>Q6. If this medication is being given via the IV route of administration, which of the following apply:</p> <p><input type="checkbox"/> The medication is being given via an infusion pump  <input type="checkbox"/> The medication is being given via IV push or infusion drip (gravity method)</p>



**COVERAGE DETERMINATION REQUEST FORM**

**EOC ID:**

Non Formulary Exception (NFE) Request-8A Medicare

**Phone: 866-250-2005 Fax back to: 877-503-7231**

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b>
----------------------	-------------------------

<input type="checkbox"/> The medication is not being administered via the IV route, it is being used SQ or IM <input type="checkbox"/> The medication is not being given via IV
<p>Q7. If being given by an infusion pump, did Medicare pay for the pump?</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>
<p>Q8. Will this medication be administered with a nebulizer?</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>
<p>Q9. Are formulary alternatives contraindicated or not appropriate for this patient? Please provide details:</p>
<p>Q10. Two formulary alternatives are required in order for a non-formulary item to be approved. • Please list the formulary alternatives that the patient has tried for the requested diagnosis. • Include the date and response to therapy (i.e. ineffective, intolerance, contraindication, etc). • Without this information, this request will be denied.</p>

Prescriber Signature	Date
----------------------	------

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document